I’ve been thinking about what turns women–OK, me–on. And by turns me on I mean interested in engaging in getting busy with my main squeeze.  I’ve been pondering this for two reasons.

The first is that earlier this week an advisory committee recommended that the FDA approve Sprout Pharmaceuticals’s drug flibanserin to treat low libido in women. (Disclosure: My husband knows the founders of this company.) Unlike Viagra, the go-to drug for male sexual dysfunction, flibanserin doesn’t treat a clear cut physical problem. As Cindy Pearson, the executive director of the National Women’s Health Network, writes this week in the Washington Post:

Viagra addresses a physical problem by easing blood flow in men who desire sex but have difficulty functioning. Flibanserin, on the other hand, addresses arousal in women who lack sexual desire by targeting neurotransmitters in the brain, our most complex organ.

Flibanserin has been rejected twice before by FDA advisory committees. Previously the agency’s studies showed the drug isn’t very effective (only 10-12% […]